PL4188420T3 - Kompozycje i sposoby związane z leczeniem chorób - Google Patents

Kompozycje i sposoby związane z leczeniem chorób

Info

Publication number
PL4188420T3
PL4188420T3 PL22712997.0T PL22712997T PL4188420T3 PL 4188420 T3 PL4188420 T3 PL 4188420T3 PL 22712997 T PL22712997 T PL 22712997T PL 4188420 T3 PL4188420 T3 PL 4188420T3
Authority
PL
Poland
Prior art keywords
diseases
compositions
treatment
methods related
methods
Prior art date
Application number
PL22712997.0T
Other languages
English (en)
Inventor
William Stimson
Original Assignee
ILC Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ILC Therapeutics Limited filed Critical ILC Therapeutics Limited
Publication of PL4188420T3 publication Critical patent/PL4188420T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL22712997.0T 2021-02-17 2022-02-16 Kompozycje i sposoby związane z leczeniem chorób PL4188420T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2102261.1A GB202102261D0 (en) 2021-02-17 2021-02-17 Compositions and methods relating to the treatment of diseases
PCT/GB2022/050406 WO2022175651A1 (en) 2021-02-17 2022-02-16 Compositions and methods relating to the treatment of diseases

Publications (1)

Publication Number Publication Date
PL4188420T3 true PL4188420T3 (pl) 2024-10-14

Family

ID=75339037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22712997.0T PL4188420T3 (pl) 2021-02-17 2022-02-16 Kompozycje i sposoby związane z leczeniem chorób

Country Status (13)

Country Link
US (1) US20240124545A1 (pl)
EP (1) EP4188420B1 (pl)
JP (1) JP2024507313A (pl)
KR (1) KR20230146504A (pl)
CN (1) CN116568318A (pl)
AU (1) AU2022223363A1 (pl)
CA (1) CA3190362A1 (pl)
ES (1) ES2981369T3 (pl)
GB (1) GB202102261D0 (pl)
HR (1) HRP20240992T1 (pl)
HU (1) HUE067796T2 (pl)
PL (1) PL4188420T3 (pl)
WO (1) WO2022175651A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523984B (zh) * 2024-11-27 2026-01-30 东莞市东南部中心医院(东莞市东南部中医医疗服务中心、广东医科大学附属东莞第一医院) 吐根碱在制备抗轮状病毒药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
EP3801599A1 (en) * 2018-06-01 2021-04-14 ILC Therapeutics Ltd Compositions and methods relating to the treatment of diseases
HUE067223T2 (hu) * 2020-03-16 2024-10-28 Ilc Therapeutics Ltd Hibrid interferonok vírusfertõzések kezelésére

Also Published As

Publication number Publication date
CN116568318A (zh) 2023-08-08
KR20230146504A (ko) 2023-10-19
ES2981369T3 (es) 2024-10-08
US20240124545A1 (en) 2024-04-18
AU2022223363A1 (en) 2023-03-23
CA3190362A1 (en) 2022-08-25
HUE067796T2 (hu) 2024-11-28
HRP20240992T1 (hr) 2024-10-25
EP4188420C0 (en) 2024-06-05
EP4188420A1 (en) 2023-06-07
EP4188420B1 (en) 2024-06-05
JP2024507313A (ja) 2024-02-19
WO2022175651A9 (en) 2022-11-03
GB202102261D0 (en) 2021-03-31
WO2022175651A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
EP3914231A4 (en) Treatment of skin disorders with topical tapinarof combination compositions
EP4146229A4 (en) COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
EP4149453A4 (en) Combination treatment of liver disorders
EP4072574A4 (en) THERAPEUTIC CELL COMPOSITIONS AND METHODS OF PRODUCTION AND METHODS OF USE THEREOF
EP3737379A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISEASES
EP4352231A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH ANGPTL4
EP4412620A4 (en) OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
EP4003006A4 (en) Compositions and methods of using multipotent stem cells to reduce disease and enhance wellness
PL4188420T3 (pl) Kompozycje i sposoby związane z leczeniem chorób
EP4413032A4 (en) TREATMENT OF MAST CELL DISORDERS
EP4384220A4 (en) Compositions and methods for treatment of cancer
EP4313024A4 (en) Treatment of inflammatory diseases
IL311867A (en) Trem compositions and methods of use
IL308083A (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
IL299632A (en) Inflammatory disease treatment using anti-tissue factor antibodies
EP4007610A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALPHA-THALASSEMIA
EP4267163A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
IL312688A (en) Methods and compositions for treating conditions associated with central hypoventilation
EP4561557A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP4412632A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASE
IL311266A (en) Compositions and methods for treating or preventing autoimmune diseases
EP4415737A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS
IL310210A (en) Methods for inhibiting the progression of oxidative retinal diseases